FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Wiltrout

Research Profile

Living Beings

Anatomy

Physiology

Cytotoxicity, Immunologic

Chemicals & Drugs

Disorders

Procedures

Co-author Network

Publications

TOP 3
Jeffrey Subleski; Veronica L Hall; Thomas B Wolfe; Anthony J Scarzello; Jonathan M Weiss; Tim Chan; Deborah L Hodge; Timothy C Back; John R Ortaldo; Robert Wiltrout
TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.
Jonathan M Weiss; Timothy C Back; Anthony J Scarzello; Jeffrey Subleski; Veronica L Hall; Jimmy K Stauffer; Xin Chen; Dejan Micic; Kory Alderson; William Murphy; Robert Wiltrout
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Jeffrey Subleski; Robert Wiltrout; Jonathan M Weiss
Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Wiltrout (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Jeffrey Subleski; Veronica L Hall; Thomas B Wolfe; Anthony J Scarzello; Jonathan M Weiss; Tim Chan; Deborah L Hodge; Timothy C Back; John R Ortaldo; Robert Wiltrout
TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(2):838-47.
2009: Jonathan M Weiss; Timothy C Back; Anthony J Scarzello; Jeffrey Subleski; Veronica L Hall; Jimmy K Stauffer; Xin Chen; Dejan Micic; Kory Alderson; William Murphy; Robert Wiltrout
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(46):19455-60.
2009: Jeffrey Subleski; Robert Wiltrout; Jonathan M Weiss
Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.
Journal of autoimmunity 2009;33(3-4):275-81.
2009: Anil Shanker; Alan D Brooks; Kristen M Jacobsen; John W Wine; Robert Wiltrout; Hideo Yagita; Thomas J Sayers
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
Cancer research 2009;69(16):6615-23.
2009: Shivaani Kummar; Robert Kinders; Martin E Gutierrez; Larry Rubinstein; Ralph E Parchment; Lawrence R Phillips; Jiuping Ji; Anne Monks; Jennifer A Low; Alice Chen; Anthony J Murgo; Jerry Collins; Seth M Steinberg; Helen Eliopoulos; Vincent L Giranda; Gary Gordon; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2705-11.
2008: S Perwez Hussain; Peijun He; Jeffrey Subleski; Lorne J Hofseth; Glennwood E Trivers; Leah E Mechanic; Anne B Hofseth; Mark Bernard; Jonathan Schwank; Giang Nguyen; Ewy Mathe; Draginja Djurickovic; Diana Haines; Jonathan Weiss; Timothy C Back; Eilene Gruys; Victor E Laubach; Robert Wiltrout; Curtis C Harris
Nitric oxide is a key component in inflammation-accelerated tumorigenesis.
Cancer research 2008;68(17):7130-6.
2008: Anthony J Murgo; Shivaani Kummar; Larry Rubinstein; Martin Gutierrez; Jerry Collins; Robert Kinders; Ralph E Parchment; Jiuping Ji; Seth M Steinberg; Sherry X Yang; Melinda G Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Designing phase 0 cancer clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3675-82.
2008: Shivaani Kummar; Larry Rubinstein; Robert Kinders; Ralph E Parchment; Martin E Gutierrez; Anthony J Murgo; Jay Ji; Barbara Mroczkowski; Oxana Pickeral; Mel Simpson; Melinda G Hollingshead; Sherry X Yang; Lee Helman; Robert Wiltrout; Jerry Collins; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trials: conceptions and misconceptions.
Cancer journal (Sudbury, Mass.) 2008;14(3):133-7.
2008: Kory L Alderson; Qing Zhou; Vanessa Berner; Danice E C Wilkins; Jonathan M Weiss; Bruce R Blazar; Lisbeth A Welniak; Robert Wiltrout; Doug Redelman; William Murphy
Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(5):2981-8.
2007: Robert Kinders; Ralph E Parchment; Jay Ji; Shivaani Kummar; Anthony J Murgo; Martin Gutierrez; Jerry Collins; Larry Rubinstein; Oxana Pickeral; Seth M Steinberg; Sherry Yang; Melinda G Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Mel Simpson; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Molecular interventions 2007;7(6):325-34.
2007: Jonathan M Weiss; Jeffrey Subleski; JON WIGGINTON; Robert Wiltrout
Immunotherapy of cancer by IL-12-based cytokine combinations.
Expert opinion on biological therapy 2007;7(11):1705-21.
2007: Marcus E Peter; Ralph C Budd; Julie Desbarats; Stephen M Hedrick; Anne-Odile Hueber; M Karen Newell; Laurie B Owen-Schaub; Richard M Pope; Juerg Tschopp; Harald Wajant; David Wallach; Robert Wiltrout; Martin Zörnig; David H Lynch
The CD95 receptor: apoptosis revisited.
Cell 2007;129(3):447-50.
2007: Chie Kudo-Saito; Elizabeth K Wansley; M Eilene Gruys; Robert Wiltrout; Jeffrey Schlom; James W Hodge
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1936-46.
2007: Vanessa Berner; Haiyan Liu; Qing Zhou; Kory L Alderson; Kai Sun; Jonathan M Weiss; Timothy C Back; Dan Longo; Bruce R Blazar; Robert Wiltrout; Lisbeth A Welniak; Doug Redelman; William Murphy
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
Nature medicine 2007;13(3):354-60.
2007: Shivaani Kummar; Robert Kinders; Larry Rubinstein; Ralph E Parchment; Anthony J Murgo; Jerry Collins; Oxana Pickeral; Jennifer Low; Seth M Steinberg; Martin Gutierrez; Sherry Yang; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Compressing drug development timelines in oncology using phase '0' trials.
Nature reviews. Cancer 2007;7(2):131-9.
2006: Jeffrey Subleski; Veronica L Hall; Timothy C Back; John R Ortaldo; Robert Wiltrout
Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.
Cancer research 2006;66(22):11005-12.
2006: H Yazawa; T Murakami; H-M Li; Timothy C Back; K Kurosaka; Y Suzuki; Lynnette Shorts; Y Akiyama; K Maruyama; E Parsoneault; Robert Wiltrout; M Watanabe
Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Cancer gene therapy 2006;13(11):993-1001.
2006: Lynnette Shorts; Jonathan M Weiss; Jong-Keuk Lee; Lisbeth A Welniak; Jeffrey Subleski; Timothy C Back; William Murphy; Robert Wiltrout
Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(11):6543-52.
2005: John R Ortaldo; Robin Winkler-Pickett; Earl W Bere; Morihiro Watanabe; William Murphy; Robert Wiltrout
In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(2):693-9.
2005: Jong-Keuk Lee; Naoko Seki; Thomas J Sayers; Jeffrey Subleski; E M Gruys; William Murphy; Robert Wiltrout
Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.
Cellular immunology 2005;235(2):145-52.
2004: S Perwez Hussain; Glennwood E Trivers; Lorne J Hofseth; Peijun He; Irfan Shaikh; Leah E Mechanic; Saira Doja; Weidong Jiang; Jeffrey Subleski; Lynnette Shorts; Diana Haines; Victor E Laubach; Robert Wiltrout; Draginja Djurickovic; Curtis C Harris
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.
Cancer research 2004;64(19):6849-53.
2004: Lisbeth A Welniak; Lynnette Shorts; Jeffrey Subleski; Bruce R Blazar; Robert Wiltrout; William Murphy
Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(8):534-9.
2004: Ana M Gamero; Howard A Young; Robert Wiltrout
Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?
Cancer cell 2004;5(2):111-2.
2004: John R Ortaldo; Howard A Young; Robin Winkler-Pickett; Earl W Bere; William Murphy; Robert Wiltrout
Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(2):943-53.
2003: Christophe Cataisson; Elizabeth Joseloff; Rodolfo Murillas; Alice Wang; Coralyn Atwell; Sara Torgerson; Michael J Gerdes; Jeffrey Subleski; Ji-Liang Gao; Philip M Murphy; Robert Wiltrout; Charles Vinson; Stuart H Yuspa
Activation of cutaneous protein kinase C alpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(5):2703-13.
2003: Jong-Keuk Lee; Thomas J Sayers; Timothy C Back; JON WIGGINTON; Robert Wiltrout
Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.
Apoptosis : an international journal on programmed cell death 2003;8(2):151-60.
2003: William Murphy; Lisbeth A Welniak; Timothy C Back; Julie A Hixon; Jeffrey Subleski; Naoko Seki; JON WIGGINTON; Susan E Wilson; Bruce R Blazar; Anatoli Malyguine; Thomas J Sayers; Robert Wiltrout
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(5):2727-33.
2003: Naoko Seki; Yoshihiro Hayakawa; Alan D Brooks; John Wine; Robert Wiltrout; Hideo Yagita; Jane E Tanner; Mark J Smyth; Thomas J Sayers
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Cancer research 2003;63(1):207-13.
2002: JON WIGGINTON; Jong-Keuk Lee; Theresa A Wiltrout; W Gregory Alvord; Julie A Hixon; Jeffrey Subleski; Timothy C Back; Robert Wiltrout
Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(8):4467-74.
2002: Yasuto Akiyama; Kouji Maruyama; Noriko Nara; Takashi Hojo; Jin-yan Cheng; Toshio Mori; Robert Wiltrout; Ken Yamaguchi
Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters.
Cancer letters 2002;184(1):37-47.
2002: JON WIGGINTON; Robert Wiltrout
IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside.
Expert opinion on biological therapy 2002;2(5):513-24.
2002: Naoko Seki; Alan D Brooks; Clive R D Carter; Timothy C Back; Erin M Parsoneault; Mark J Smyth; Robert Wiltrout; Thomas J Sayers
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(7):3484-92.
2002: Julie A Hixon; Miriam R Anver; Bruce R Blazar; Angela Panoskaltsis-Mortari; Robert Wiltrout; William Murphy
Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(6):316-25.
2001: M Eilene Gruys; Timothy C Back; Jeffrey Subleski; Theresa A Wiltrout; J K Lee; L Schmidt; M Watanabe; R Stanyon; J M Ward; JON WIGGINTON; Robert Wiltrout
Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.
Cancer research 2001;61(16):6255-63.
2001: Jong-Keuk Lee; Timothy C Back; Kristin L Komschlies; F W Ruscetti; Howard A Young; Robert Wiltrout
Hematopoietic switch from lymphoid to granulocytic development in 3LL tumor-bearing mice.
In vivo (Athens, Greece) 2001;15(4):255-63.
2001: JON WIGGINTON; E Gruys; L Geiselhart; Jeffrey Subleski; Kristin L Komschlies; JW Park; Theresa A Wiltrout; K Nagashima; Timothy C Back; Robert Wiltrout
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
The Journal of clinical investigation 2001;108(1):51-62.
2001: M J Smyth; Erika Cretney; K Takeda; Robert Wiltrout; Lisa M Sedger; Nobuhiko Kayagaki; H Yagita; K Okumura
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
The Journal of experimental medicine 2001;193(6):661-70.
2001: JW Park; M Eilene Gruys; K McCormick; Jong-Keuk Lee; Jeffrey Subleski; JON WIGGINTON; Robert G Fenton; J M Wang; Robert Wiltrout
Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).
Journal of immunology (Baltimore, Md. : 1950) 2001;166(6):3763-70.
2001: Lisbeth A Welniak; Annette Khaled; Miriam R Anver; Kristin L Komschlies; Robert Wiltrout; Scott K Durum; F R Ruscetti; B R Blazar; William Murphy
Gastrointestinal cells of IL-7 receptor null mice exhibit increased sensitivity to irradiation.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(5):2924-8.
2001: Zhenyu Zhu; Otto Sanchez-Sweatman; Xiaojun Huang; Robert Wiltrout; Rama Khokha; Qun Zhao; Elieser Gorelik
Anoikis and metastatic potential of cloudman S91 melanoma cells.
Cancer research 2001;61(4):1707-16.
2001: Lisbeth A Welniak; B R Blazar; Robert Wiltrout; Miriam R Anver; William Murphy
Role of interleukin-12 in acute graft-versus-host disease(1).
Transplantation proceedings 2001;33(1-2):1752-3.
2001: JON WIGGINTON; JW Park; M Eilene Gruys; Howard A Young; Cheryl Jorcyk; Timothy C Back; MJ Brunda; R M Strieter; J Ward; Jeffrey E Green; Robert Wiltrout
Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(2):1156-68.
2001: Julie A Hixon; Bruce R Blazar; Miriam R Anver; Robert Wiltrout; William Murphy
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2001;7(3):136-43.
2000: Yasuto Akiyama; M Watanabe; Kouji Maruyama; F W Ruscetti; Robert Wiltrout; Ken Yamaguchi
Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Gene therapy 2000;7(24):2113-21.
2000: T Hoshino; H Yagita; John R Ortaldo; Robert Wiltrout; H A Young
In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells.
European journal of immunology 2000;30(7):1998-2006.
2000: Robert Wiltrout
Regulation and antimetastatic functions of liver-associated natural killer cells.
Immunological reviews 2000;174():63-76.
2000: Jeffrey E Green; MA Shibata; K Yoshidome; ML Liu; Cheryl Jorcyk; Miriam R Anver; JON WIGGINTON; Robert Wiltrout; E Shibata; Stanislaw J Kaczmarczyk; W Wang; Z Y Liu; Alfonso Calvo; Christine Couldrey
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Oncogene 2000;19(8):1020-7.
2000: Lisbeth A Welniak; B R Blazar; Miriam R Anver; Robert Wiltrout; William Murphy
Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(6):604-12.
2000: Jong-Keuk Lee; Thomas J Sayers; Alan D Brooks; Timothy C Back; Howard A Young; Kristin L Komschlies; JON WIGGINTON; Robert Wiltrout
IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(1):231-9.
1999: D Ito; T C Back; Alexander N Shakhov; Robert Wiltrout; Sergei A Nedospasov
Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(5):2809-15.
1999: M Watanabe; Robert G Fenton; JON WIGGINTON; K L McCormick; Kirk M Volker; William E Fogler; P G Roessler; Robert Wiltrout
Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(4):1943-50.
1999: T Hoshino; Robert Wiltrout; Howard A Young
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(9):5070-7.
1998: William E Fogler; Kirk M Volker; M Watanabe; JON WIGGINTON; P Roessler; MJ Brunda; John R Ortaldo; Robert Wiltrout
Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(11):6014-21.
1998: William Murphy; Lisbeth A Welniak; D D Taub; Robert Wiltrout; Patricia A Taylor; DA Vallera; M Kopf; H Young; Dan Longo; Bruce R Blazar
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
The Journal of clinical investigation 1998;102(9):1742-8.
1998: Thomas J Sayers; Alan D Brooks; Jong-Keuk Lee; Robert G Fenton; Kristin L Komschlies; JON WIGGINTON; Robin Winkler-Pickett; Robert Wiltrout
Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(8):3957-65.
1998: W M Siders; P W Wright; Julie A Hixon; W Gregory Alvord; Timothy C Back; Robert Wiltrout; Robert G Fenton
T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(11):5465-74.
1997: Peter F A Mulders; Robert Figlin; Jean B deKernion; Robert Wiltrout; M Linehan; D Parkinson; W deWolf; Arie Belldegrun
Renal cell carcinoma: recent progress and future directions.
Cancer research 1997;57(22):5189-95.
1997: M Watanabe; K L McCormick; Kirk M Volker; John R Ortaldo; JON WIGGINTON; MJ Brunda; Robert Wiltrout; William E Fogler
Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.
The American journal of pathology 1997;150(5):1869-80.
1997: Nicola J Brown; S Ali; M W R Reed; Robert Wiltrout; R C Rees
Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.
British journal of cancer 1997;76(12):1572-8.
1996: K J Grzegorzewski; Kristin L Komschlies; J L Franco; Francis W Ruscetti; Jonathan Keller; Robert Wiltrout
Quantitative and cell-cycle differences in progenitor cells mobilized by recombinant human interleukin-7 and recombinant human granulocyte colony-stimulating factor.
Blood 1996;88(11):4139-48.
1996: JON WIGGINTON; Kristin L Komschlies; Jeffrey E Green; G W Cox; Cheryl Jorcyk; T C Back; J L Franco; M J Brunda; Robert Wiltrout
Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination.
Annals of the New York Academy of Sciences 1996;795():434-9.
1996: M J Brunda; L Luistro; L Rumennik; R B Wright; JON WIGGINTON; Robert Wiltrout; J A Hendrzak; AV Palleroni
Interleukin-12: murine models of a potent antitumor agent.
Annals of the New York Academy of Sciences 1996;795():266-74.
1996: C R Carter; Thomas J Sayers; Robert Wiltrout; SM Turcovski-Corrales; D D Taub
Generation of antigenic peptides by lymphocyte granule serine proteases (granzymes).
Cellular immunology 1996;172(2):235-45.
1996: William E Fogler; Kirk M Volker; K L McCormick; M Watanabe; John R Ortaldo; Robert Wiltrout
NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(12):4707-14.
1996: Thomas J Sayers; A R Lloyd; Daniel W McVicar; M D O'Connor; J M Kelly; C R Carter; TA Wiltrout; Robert Wiltrout; Mark J Smyth
Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3.
Journal of leukocyte biology 1996;59(5):763-8.
1996: JON WIGGINTON; D B Kuhns; T C Back; M J Brunda; Robert Wiltrout; G W Cox
Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2.
Cancer research 1996;56(5):1131-6.
1996: JON WIGGINTON; Kristin L Komschlies; T C Back; J L Franco; M J Brunda; Robert Wiltrout
Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.
Journal of the National Cancer Institute 1996;88(1):38-43.
1996: N Usui; K Matsushima; A M Pilaro; Dan Longo; Robert Wiltrout
Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
Biotherapy (Dordrecht, Netherlands) 1996;9(4):199-208.
1996: M J Brunda; L Luistro; L Rumennik; R B Wright; M Dvorozniak; A Aglione; JON WIGGINTON; Robert Wiltrout; J A Hendrzak; AV Palleroni
Antitumor activity of interleukin 12 in preclinical models.
Cancer chemotherapy and pharmacology 1996;38 Suppl():S16-21.
1995: Kristin L Komschlies; K J Grzegorzewski; Robert Wiltrout
Diverse immunological and hematological effects of interleukin 7: implications for clinical application.
Journal of leukocyte biology 1995;58(6):623-33.
1995: P Ghosh; Kristin L Komschlies; M Cippitelli; Dan Longo; J Subleski; J Ye; A Sica; Howard A Young; Robert Wiltrout; Augusto C Ochoa
Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.
Journal of the National Cancer Institute 1995;87(19):1478-83.
1995: J L Franco; P Ghosh; Robert Wiltrout; C R Carter; Arnold H Zea; N Momozaki; Augusto C Ochoa; Dan Longo; Thomas J Sayers; Kristin L Komschlies
Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.
Cancer research 1995;55(17):3840-6.
1995: Otto Boerman; T A Gregorio; K J Grzegorzewski; C R Faltynek; J J Kenny; Robert Wiltrout; Kristin L Komschlies
Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants.
Journal of leukocyte biology 1995;58(2):151-8.
1995: Robert Wiltrout; T A Gregorio; Robert G Fenton; Dan Longo; P Ghosh; William Murphy; Kristin L Komschlies
Cellular and molecular studies in the treatment of murine renal cancer.
Seminars in oncology 1995;22(1):9-16.
1995: William E Fogler; J W Pearson; Kirk M Volker; K Ariyoshi; H Watabe; C W Riggs; Robert Wiltrout; Dan Longo
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Journal of the National Cancer Institute 1995;87(2):94-104.
1995: J T Holmund; William Kopp; Robert Wiltrout; Dan Longo; W J Urba; John Janik; Mario Sznol; K C Conlon; Robert G Fenton; R Hornung
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.
Journal of the National Cancer Institute 1995;87(2):134-6.
1995: K J Grzegorzewski; Kristin L Komschlies; Sten Eirik W Jacobsen; Francis W Ruscetti; Jonathan Keller; Robert Wiltrout
Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7.
The Journal of experimental medicine 1995;181(1):369-74.
1994: K Grzegorzewski; Francis W Ruscetti; N Usui; G Damia; Dan Longo; J A Carlino; Jonathan Keller; Robert Wiltrout
Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.
The Journal of experimental medicine 1994;180(3):1047-57.
1994: A M Pilaro; D D Taub; K L McCormick; H M Williams; Thomas J Sayers; William E Fogler; Robert Wiltrout
TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(1):333-42.
1994: Kristin L Komschlies; T A Gregorio; M E Gruys; T C Back; C R Faltynek; Robert Wiltrout
Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(12):5776-84.
1994: P Ghosh; A Sica; Howard A Young; J Ye; J L Franco; Robert Wiltrout; Dan Longo; N R Rice; Kristin L Komschlies
Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy.
Cancer research 1994;54(11):2969-72.
1994: K Kaneda; A M Pilaro; Thomas J Sayers; K Nagashima; M A Gonda; John R Ortaldo; Robert Wiltrout
Quantitative analysis of rod-cored vesicles and dense granules of large granular lymphocytes in the liver, spleen, and peripheral blood of rats.
Cell and tissue research 1994;276(1):187-95.
1994: Martin MacPhee; Robert Wiltrout; K L McCormick; Thomas J Sayers; A M Pilaro
A method for obtaining and culturing large numbers of purified organ-derived murine endothelial cells.
Journal of leukocyte biology 1994;55(4):467-75.
1994: K Grzegorzewski; Kristin L Komschlies; M Mori; K Kaneda; N Usui; C R Faltynek; Jonathan Keller; Francis W Ruscetti; Robert Wiltrout
Administration of recombinant human interleukin-7 to mice induces the exportation of myeloid progenitor cells from the bone marrow to peripheral sites.
Blood 1994;83(2):377-85.
1994: Kristin L Komschlies; T T Back; T A Gregorio; M E Gruys; G Damia; Robert Wiltrout; C R Faltynek
Effects of rhIL-7 on leukocyte subsets in mice: implications for antitumor activity.
Immunology series 1994;61():95-104.
1993: James H Finke; Arnold H Zea; J Stanley; Dan Longo; H Mizoguchi; Raymond R Tubbs; Robert Wiltrout; John O'Shea; S Kudoh; E Klein
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Cancer research 1993;53(23):5613-6.
1993: William Murphy; T C Back; K C Conlon; Kristin L Komschlies; John R Ortaldo; Thomas J Sayers; Robert Wiltrout; Dan Longo
Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
The Journal of clinical investigation 1993;92(4):1918-24.
1993: J W Pearson; William E Fogler; Kirk M Volker; C W Riggs; E Gruys; E S Groves; Robert Wiltrout; Dan Longo
Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Journal of the National Cancer Institute 1993;85(11):907-12.
1993: William Murphy; K C Conlon; Thomas J Sayers; Robert Wiltrout; T C Back; John R Ortaldo; Dan Longo
Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(8 Pt 1):3634-42.
1993: Thomas J Sayers; L H Mason; A Pilaro; TA Wiltrout; Kristin L Komschlies; W L Munger; Robert Wiltrout
Substrate-specific proteases (BLT-esterase) are localized predominantly in the natural killer cells of unprimed mice.
Journal of leukocyte biology 1993;53(4):454-61.
1993: R Forough; Z Xi; Martin MacPhee; S Friedman; K A Engleka; T Sayers; Robert Wiltrout; Thomas Maciag
Differential transforming abilities of non-secreted and secreted forms of human fibroblast growth factor-1.
The Journal of biological chemistry 1993;268(4):2960-8.
1992: H Futami; L Eader; T T Back; E Gruys; H A Young; Robert Wiltrout; B C Baguley
Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):247-55.
1992: G Damia; Kristin L Komschlies; H Futami; T Back; M E Gruys; Dan Longo; Jonathan Keller; F W Ruscetti; Robert Wiltrout
Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.
Cancer research 1992;52(15):4082-9.
1992: G Damia; Kristin L Komschlies; C R Faltynek; F W Ruscetti; Robert Wiltrout
Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice.
Blood 1992;79(5):1121-9.
1992: E Ayroldi; E Blasi; Luigi Varesio; Robert Wiltrout
Inhibition of proliferation of retrovirus-immortalized macrophages by LPS and IFN-gamma: possible autocrine down-regulation of cell growth by induction of IL1 and TNF.
Biotherapy (Dordrecht, Netherlands) 1992;4(4):267-76.
1991: H Futami; L A Eader; Kristin L Komschlies; R Bull; M E Gruys; John R Ortaldo; Howard A Young; Robert Wiltrout
Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes.
Cancer research 1991;51(24):6596-602.
1991: R Jansen; G Damia; N Usui; J Keller; H Futami; H Goey; T T Back; Dan Longo; F W Ruscetti; Robert Wiltrout
Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(10):3342-7.
1991: J W Pearson; William E Fogler; Kirk M Volker; N Usui; S K Goldenberg; E Gruys; C W Riggs; Kristin L Komschlies; Robert Wiltrout; T Tsuruo
Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.
Journal of the National Cancer Institute 1991;83(19):1386-91.
1991: H Futami; A M Pilaro; M E Gruys; T C Back; Howard A Young; Robert Wiltrout
In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells.
Biotherapy (Dordrecht, Netherlands) 1991;3(3):219-32.
1991: Francis W Ruscetti; C Dubois; L A Falk; S E Jacobsen; G Sing; Dan Longo; Robert Wiltrout; Jonathan Keller
In vivo and in vitro effects of TGF-beta 1 on normal and neoplastic haemopoiesis.
Ciba Foundation symposium 1991;157():212-27; discussion 227-31.
1990: A M Pilaro; Thomas J Sayers; K L McCormick; C W Reynolds; Robert Wiltrout
An improved in vitro assay to quantitate chemotaxis of rat peripheral blood large granular lymphocytes (LGL).
Journal of immunological methods 1990;135(1-2):213-23.
1990: H Futami; R Jansen; Martin MacPhee; J Keller; K McCormick; Dan Longo; J J Oppenheim; F W Ruscetti; Robert Wiltrout
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(12):4121-30.
1990: H Futami; R L Hornung; T T Back; R Bull; E Gruys; Robert Wiltrout
Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
Cancer research 1990;50(24):7926-31.
1990: J R Ortaldo; Robert Wiltrout
Implications of potential positive correlation between autologous tumor-cell-killing activity and prognosis in lung cancer.
Journal of the National Cancer Institute 1990;82(21):1663-5.
1990: J W Pearson; E Hedrick; William E Fogler; R L Bull; Douglass K Ferris; C W Riggs; Robert Wiltrout; G Sivam; AC Morgan; E Groves
Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
Cancer research 1990;50(19):6379-88.
1990: Thomas J Sayers; TA Wiltrout; K McCormick; C Husted; Robert Wiltrout
Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Cancer research 1990;50(17):5414-20.
1990: K F Mace; R L Hornung; Robert Wiltrout; Howard A Young
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer.
Cancer research 1990;50(6):1742-7.
1990: R C Rees; Robert Wiltrout
The biology and clinical applications of interleukin 2.
Immunology today 1990;11(2):36-8.
1989: J W Pearson; G Sivam; R Manger; Robert Wiltrout; AC Morgan; Dan Longo
Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
Cancer research 1989;49(18):4990-5.
1989: H Goey; Jonathan Keller; T Back; Dan Longo; F W Ruscetti; Robert Wiltrout
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(3):877-80.
1989: Robert Wiltrout; A M Pilaro; M E Gruys; James Edward Talmadge; Dan Longo; John R Ortaldo; C W Reynolds
Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(1):372-8.
1989: J W Pearson; D J FitzGerald; M C Willingham; Robert Wiltrout; Ira Pastan; Dan Longo
Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice.
Cancer research 1989;49(13):3562-7.
1988: R L Hornung; T C Back; D S Zaharko; W J Urba; Dan Longo; Robert Wiltrout
Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(10):3671-9.
1988: R L Hornung; Howard A Young; W J Urba; Robert Wiltrout
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta.
Journal of the National Cancer Institute 1988;80(15):1226-31.
1988: J R Ortaldo; B J Mathieson; Robert Wiltrout
Characterization and functions of natural killer cells.
Annales de l'Institut Pasteur. Immunology 1988;139(4):444-50.
1988: Robert Wiltrout; M R Boyd; T C Back; R R Salup; J A Arthur; R L Hornung
Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(9):3261-5.
1988: Robert Wiltrout; R L Hornung
Natural products as antitumor agents: direct versus indirect mechanisms of activity of flavonoids.
Journal of the National Cancer Institute 1988;80(4):220-2.
1988: Robert Wiltrout; R R Salup
Adoptive immunotherapy in combination with chemotherapy for cancer treatment.
Progress in experimental tumor research 1988;32():128-53.
1988: Elisabetta Blasi; Luigi Varesio; Robert Wiltrout
Tumor formation by a murine macrophage cell line immortalized in vitro by v-raf and v-myc oncogenes.
Cancer immunology, immunotherapy : CII 1988;27(2):109-13.
1987: R R Salup; B J Mathieson; Robert Wiltrout
Precursor phenotype of lymphokine-activated killer cells in the mouse.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(11):3635-9.
1987: James Edward Talmadge; H R Tribble; R W Pennington; H Phillips; Robert Wiltrout
Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
Cancer research 1987;47(10):2563-70.
1987: R R Salup; T C Back; Robert Wiltrout
Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(2):641-7.
1987: Robert Wiltrout; B J Mathieson; T C Back; R R Salup
Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy.
Progress in clinical and biological research 1987;244():17-25.
1987: T A Twilley; L Mason; J E Talmadge; Robert Wiltrout
Increase in liver-associated natural killer activity by polyribonucleotides.
Natural immunity and cell growth regulation 1987;6(6):279-90.
1986: J E Talmadge; Robert Wiltrout; D F Counts; R B Herberman; T McDonald; J R Ortaldo
Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.
Cellular immunology 1986;102(2):261-72.
1986: R R Salup; Robert Wiltrout
Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
Cancer research 1986;46(7):3358-63.
1986: Robert Wiltrout; A C Denn; C W Reynolds
Augmentation of organ-associated NK activity by BRMs: association of NK activity with mononuclear cell infiltration.
Pathology and immunopathology research 1986;5(3-5):219-33.
1986: R R Salup; Robert Wiltrout
Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.
Cancer immunology, immunotherapy : CII 1986;22(1):31-6.
1986: S R Zhang; R R Salup; P E Urias; T A Twilley; J E Talmadge; R B Herberman; Robert Wiltrout
Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2.
Cancer immunology, immunotherapy : CII 1986;21(1):19-25.
1985: R R Salup; R B Herberman; Robert Wiltrout
Role of natural killer activity in development of spontaneous metastases in murine renal cancer.
The Journal of urology 1985;134(6):1236-41.
1985: Robert Wiltrout; R R Salup; T A Twilley; J E Talmadge
Immunomodulation of natural killer activity by polyribonucleotides.
Journal of biological response modifiers 1985;4(5):512-7.
1985: J E Talmadge; M Schneider; M Collins; H Phillips; R B Herberman; Robert Wiltrout
Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(2):1477-83.
1985: Robert Wiltrout; R B Herberman; S R Zhang; M A Chirigos; J R Ortaldo; K M Green; J E Talmadge
Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(6):4267-75.
1985: Robert Wiltrout; A Santoni; E S Peterson; D C Knott; W R Overton; R B Herberman; H T Holden
Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages.
Journal of leukocyte biology 1985;37(5):597-614.
1985: E Gorelik; Robert Wiltrout; M J Brunda; W E Bere; R B Herberman
Influence of adoptively transferred thioglycollate-elicited peritoneal macrophages on metastasis formation in mice with depressed or stimulated NK activity.
Clinical & experimental metastasis 1985;3(2):111-23.
1985: T Barlozzari; J Leonhardt; Robert Wiltrout; R B Herberman; C W Reynolds
Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(4):2783-9.
1985: A Santoni; M Piccoli; J R Ortaldo; L Mason; Robert Wiltrout; R B Herberman
Changes in number and density of large granular lymphocytes upon in vivo augmentation of mouse natural killer activity.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(4):2799-810.
1985: J E Talmadge; J Adams; H Phillips; M Collins; B Lenz; M Schneider; E Schlick; R Ruffmann; Robert Wiltrout; M A Chirigos
Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
Cancer research 1985;45(3):1058-65.
1985: E S Kleinerman; Robert Wiltrout; R Zicht; I J Fidler
Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.
Cancer immunology, immunotherapy : CII 1985;20(2):151-7.
1985: R R Salup; R B Herberman; M A Chirigos; T Back; Robert Wiltrout
Therapy of peritoneal murine cancer with biological response modifiers.
Journal of immunopharmacology 1985;7(4):417-36.
1985: E Gorelik; Robert Wiltrout; D Copeland; R B Herberman
Modulation of formation of tumor metastases by peritoneal macrophages elicited by various agents.
Cancer immunology, immunotherapy : CII 1985;19(1):35-42.
1984: J E Talmadge; A E Maluish; M Collins; M Schneider; R B Herberman; R K Oldham; Robert Wiltrout
Immunomodulation and antitumor effects of MVE-2 in mice.
Journal of biological response modifiers 1984;3(6):634-52.
1984: Robert Wiltrout; B J Mathieson; James Edward Talmadge; C W Reynolds; S R Zhang; R B Herberman; J R Ortaldo
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver.
The Journal of experimental medicine 1984;160(5):1431-49.
1984: L Varesio; E Blasi; Gary Thurman; James Edward Talmadge; Robert Wiltrout; R B Herberman
Potent activation of mouse macrophages by recombinant interferon-gamma.
Cancer research 1984;44(10):4465-9.
1984: Frederick Nestel; P R Casson; Robert Wiltrout; R S Kerbel
Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants.
Journal of the National Cancer Institute 1984;73(2):483-91.
1984: C W Reynolds; A C Denn; T Barlozzari; Robert Wiltrout; D A Reichardt; R B Herberman
Natural killer activity in the rat. IV. Distribution of large granular lymphocytes (LGL) following intravenous and intraperitoneal transfer.
Cellular immunology 1984;86(2):371-80.
1983: Robert Wiltrout; M J Brunda; E Gorelik; E S Peterson; J J Dunn; J Leonhardt; L Varesio; C W Reynolds; H T Holden
Distribution of peritoneal macrophage populations after intravenous injection in mice: differential effects of eliciting and activating agents.
Journal of the Reticuloendothelial Society 1983;34(3):253-69.
1983: M J Brunda; Robert Wiltrout; H T Holden; L Varesio
Selective inhibition by monosaccharides of tumor cell cytotoxicity mediated by mouse macrophages, macrophage-like cell lines, and natural killer cells.
International journal of cancer. Journal international du cancer 1983;31(3):373-9.
1983: Robert Wiltrout; E Gorelik; M J Brunda; H T Holden; R B Herberman
Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.
Cancer immunology, immunotherapy : CII 1983;14(3):172-9.
1982: Robert Wiltrout; M J Brunda; H T Holden
Variation in selectivity of tumor cell cytolysis by murine macrophages, macrophage-like cell lines and NK cells.
International journal of cancer. Journal international du cancer 1982;30(3):335-42.
1982: E Gorelik; Robert Wiltrout; K Okumura; S Habu; R B Herberman
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.
International journal of cancer. Journal international du cancer 1982;30(1):107-12.
1982: E Gorelik; Robert Wiltrout; M J Brunda; H T Holden; R B Herberman
Augmentation of metastasis formation by thioglycollate-elicited macrophages.
International journal of cancer. Journal international du cancer 1982;29(5):575-81.
1981: Robert Wiltrout; D Taramelli; H T Holden
Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine.
Journal of immunological methods 1981;43(3):319-31.
1980: Robert Wiltrout; P Frost
Cell-mediated cytotoxic responses induced in vivo and in vitro by a metastatic murine tumor.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(5):2254-63.
1980: Robert Wiltrout; P Frost; M K Morrison
Immune regression of visceral metastases in athymic mice. Correlation of "low-level" in vitro cell-mediated cytotoxic reactions with allograft rejection in vivo.
Transplantation 1980;29(4):283-86.
1979: Robert Wiltrout; P Frost; M K Morrison; R S Kerbel
Immune-mediated arrest and reversal of established visceral metastases in athymic mice.
Cancer research 1979;39(10):4034-41.
1978: Robert Wiltrout; C D Ercegovich; W S Ceglowski
Humoral immunity in mice following oral administration of selected pesticides.
Bulletin of environmental contamination and toxicology 1978;20(3):423-31.
1978: Robert Wiltrout; P Frost; G D Cummings
Isotope-release cytotoxicity assay with the use of indium-111: advantage over chromium-51 in long-term assays.
Journal of the National Cancer Institute 1978;61(1):183-8.
1977: P Frost; Robert Wiltrout; Z Maciorowski; Noel R Rose
An isotope release cytotoxicity assay applicable to human tumors: the use of 111indium.
Oncology 1977;34(3):102-4.